Raoul S. Concepcion, MD, FACS, Urology Associates P.C., Nashville, Tennessee, discusses what combinations of immunotherapy for prostate cancer treatment are most promising.
Interview produced by Prostatepedia
Keywords: combination immuonotherapy, enzalutamide, abiraterone, Provenge, Radium 223, prostate cancer
Summary:
Raoul S. Concepcion, MD, FACS, discusses managing prostate cancer with a combination of immunotherapeutic agents and other treatment options. Sipuleucel-T (PROVENGE), the only FDA approved immunotherapy for metastatic castration-resistant prostate cancer (mCRPC), does not attack androgen receptors. Therefore, Dr. Concepcion explores the possibility combining sipuleucel-T with androgen excess inhibitors, like abiraterone or enzalutamide, or a sipuleucel-T/radium-223 combination.
Dr. Concepcion further discusses combination treatments and the topic of using immunotherapy for prostate cancer in his lecture What’s New in Immunotherapy?
View more Presentations on Immunotherapy
ABOUT THE AUTHOR
Raoul S. Concepcion, MD, FACS, is the Chief Science Officer of U.S. Urology Partners in Nolensville, Tennessee. He was a resident in General Surgery and Urology at Vanderbilt University from 1984-1990, and later served as a Clinical Associate Professor of Urology there.
Dr. Concepcion’s clinical interests revolve around advanced prostate and bladder cancer management. He is a past President of LUGPA. Along with two other urologists, he founded CUSP, a urologic research consortium in the United States. Additionally, he is an advisor and/or speaker for many companies, including Dendreon, Pfizer, Astellas, Amgen, Cellay, and Janssen, and has served as editor for Urologists in Cancer Care.
